Exercise capacity in atrial fibrillation: A substudy of the Sotalol-Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) - 09/08/11
, Jonathan N. Myers, PhD e, X. Charlene Tang, MD, PhD d, Domenic J. Reda, PhD d, Steven N. Singh, MD b, Bramah N. Singh, MD, PhD cRésumé |
Background |
Therapy for chronic atrial fibrillation (AF) focuses on rate versus rhythm control, but little is known about the effects of common therapeutic interventions on exercise tolerance in AF.
Methods |
Six hundred fifty-five patients with chronic AF underwent maximal exercise testing at baseline and 8 weeks, 6 months, and 1 year after randomization to sotalol, amiodarone, or placebo therapy and attempted direct current cardioversion. Analyses of baseline determinants of exercise capacity, predictors of change in exercise capacity at 6 months and 1 year, and the short- and long-term effects of cardioversion on exercise capacity were made.
Results |
Age, obesity, and presence of symptoms accompanying AF were inversely associated with baseline exercise capacity, but these factors accounted for only 10% of the variance in exercise capacity. Patients most likely to benefit from cardioversion were those most limited initially, younger, not obese or hypertensive, and with an uncontrolled ventricular rate at baseline. Conversion to sinus rhythm (SR) resulted in significant reductions in resting (≈25 beat/min) and peak exercise (≈40 beat/min) heart rates at 6 months and 1 year (P < .001). Successful cardioversion improved exercise capacity by 15% at 8 weeks, and these improvements were maintained throughout the year. This improvement was observed both among those who maintained SR and those with intermittent AF.
Conclusion |
Cardioversion resulted in a sustained improvement in exercise capacity over the course of 1 year, and this improvement was similar between those in SR and those with SR and recurrent AF. Patients most likely to improve with treatment tended to be younger and nonobese and have the greatest limitations initially.
Le texte complet de cet article est disponible en PDF.Plan
| This study was supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development (Washington, DC), Berlex Laboratories (Montville, IL) and Wyeth-Ayerst Laboratories (Philadelphia, PA). |
Vol 153 - N° 4
P. 566-572 - avril 2007 Retour au numéro
Article précédent
- Insulin resistance is associated with increased risk of major cardiovascular events in patients with preexisting coronary artery disease
- Alexander Tenenbaum, Yehuda Adler, Valentina Boyko, Helena Tenenbaum, Enrique Z. Fisman, David Tanne, Mordechai Lapidot, Ehud Schwammenthal, Micha S. Feinberg, Zipora Matas, Michael Motro, Solomon Behar
- Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: Mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
- Michael G. Dickinson, John H. Ip, Brian Olshansky, Anne S. Hellkamp, Jill Anderson, Jeanne E. Poole, Daniel B. Mark, Kerry L. Lee, Gust H. Bardy, for the SCD-HeFT Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?